Loading
Since 2023 the stage of womb cancer includes its histological type and, where tested, its molecular class, so two tumours of the same size can now carry different stages.
FIGO's 2023 revision (Berek and colleagues, International Journal of Gynecology and Obstetrics 2023) replaced the 2009 staging. Stage I is split into IA1 to IA3, IB and IC by histological type, depth of invasion into the muscle and lymphovascular space invasion, with aggressive types (serous, high-grade endometrioid, clear cell, carcinosarcoma and others) moved to IC or IIC; stage II separates cervical stromal invasion, substantial lymphovascular invasion and aggressive types with any muscle invasion; stage III and IV substages separate adnexal from serosal spread, pelvic from para-aortic nodes, and pelvic from extrapelvic peritoneal and distant spread. Molecular classification (POLEmut, MMRd, NSMP, p53abn) is encouraged for all; when known it is added to the stage (for example IAmPOLEmut or IICmp53abn), and in stages I and II p53abn or POLEmut moves the stage up or down.
Most high-grade ovarian cancers begin at the tip of the fallopian tube; endometrial cancer lines the uterus, cervical cancer starts at the transformation zone; each drains to a different node group.
Same organ: Adenosquamous carcinoma of the cervix, Small cell neuroendocrine carcinoma of the cervix, Bartholin gland carcinoma, Vulvar melanoma, Vaginal melanoma, High-grade serous ovarian cancer, Low-grade serous ovarian cancer, Clear cell ovarian cancer, Mucinous ovarian cancer, Adult granulosa cell tumour of the ovary, Ovarian cancer, Cervical cancer, Vulvar cancer, Gestational trophoblastic neoplasia, Uterine sarcoma, Vaginal cancer, POLE-ultramutated endometrial cancer, Mismatch-repair-deficient endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer with no specific molecular profile, Advanced or recurrent endometrial cancer, Uterine carcinosarcoma, Early cervical cancer and fertility-sparing surgery, Locally advanced cervical cancer, Recurrent or metastatic cervical cancer, Platinum-sensitive ovarian cancer, Platinum-resistant ovarian cancer, HPV-associated vulvar squamous cell carcinoma, HPV-independent vulvar squamous cell carcinoma (p53-mutant), Vaginal squamous cell carcinoma (HPV-associated), Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma), Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6), High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk), Placental-site trophoblastic tumour and epithelioid trophoblastic tumour
Showing the organ this term concerns: Endometrial cancer.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), TNM staging.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/